Regulatory pathways, cleared imaging products, intended use, lifecycle oversight, and status distinctions in imaging AI.
FDA-cleared imaging AI is often used as shorthand for product maturity, but clearance alone does not resolve workflow fit, performance quality, or clinical utility. Imaging buyers still need precise language around intended use, regulatory pathway, and postmarket responsibilities.
This section tracks the regulatory side of imaging AI with an emphasis on accuracy in terminology and practical implications for clinical adoption.
The FDA now reports more than 1,600 authorized AI-enabled medical devices, a milestone that shows market growth but not product quality or local clinical fit.
Aidoc has formed a 12-system Diagnostic AI Consortium as a Medicare add-on payment creates a new adoption opening for its Body CT Multi-Triage software.
FDA clearance is an important signal for clinical AI, but it is not the whole evaluation. Research teams and hospital buyers need to read clearance, intended use, change control, local validation, and post-deployment monitoring together.
FDA-cleared AI diagnostic software should be evaluated by intended use, clearance pathway, clinical evidence, transparency, updates, workflow fit, and monitoring.
Radiology AI is one of the most active clinical AI categories, but the real test is not the demo. It is whether the tool fits reading-room workflow, integrates with PACS and reporting, holds up under local validation, and can be monitored safely after go-live.